Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Anika Therapeutics
(NASDAQ:ANIK)
Intraday
$25.57
-0.01
[-0.04%]
After-Hours
$25.57
0
[0.00%]
Get Report
Watch
Perks
Buy
Compare Brokers
$25.57
-0.01
[-0.04%]
At close: Apr 26
$25.57
0
[0.00%]
After Hours: 4:20PM EDT
Get Report
Watch
Q1 2024 Earnings in 11 days from now on Wed May 8th, after the market close
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Anika Therapeutics Stock (NASDAQ:ANIK)
Anika Therapeutics Stock (NASDAQ: ANIK)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, March 14, 2024
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $37
Benzinga Newsdesk
-
Mar 14, 2024, 10:15AM
Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $22 Price Target
Benzinga Newsdesk
-
Mar 14, 2024, 9:55AM
Wednesday, March 13, 2024
Anika Therapeutics: Q4 Earnings Insights
Benzinga Insights
-
Mar 13, 2024, 4:40PM
Anika Therapeutics Q4 2023 Adj EPS $0.05 Beats $(0.26) Estimate, Sales $42.971M Beat $41.405M Estimate
Benzinga Newsdesk
-
Mar 13, 2024, 4:36PM
Anika Therapeutics Sees FY24 Revenue $168M-$173M Vs $179.42M Est.
Benzinga Newsdesk
-
Mar 13, 2024, 4:35PM
Earnings Scheduled For March 13, 2024
Benzinga Insights
-
Mar 13, 2024, 6:15AM
Tuesday, March 12, 2024
Earnings Outlook For Anika Therapeutics
Benzinga Insights
-
Mar 12, 2024, 11:00AM
Wednesday, January 03, 2024
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $29
Benzinga Newsdesk
-
Jan 3, 2024, 10:12AM
Tuesday, November 28, 2023
Anika Announces First Surgeries Performed Using The Integrity Implant System, A Regenerative Hyaluronic Acid-Based Patch System For Rotator Cuff Repairs, Commencing Limited Market Release
Benzinga Newsdesk
-
Nov 28, 2023, 9:36AM
Friday, November 03, 2023
Barrington Research Maintains Outperform on Anika Therapeutics, Raises Price Target to $28
Benzinga Newsdesk
-
Nov 3, 2023, 12:05PM
Thursday, November 02, 2023
Anika Therapeutics Sees FY23 Revenue $164M-$166M Vs $161.29M Est.
Benzinga Newsdesk
-
Nov 2, 2023, 5:57PM
Anika Therapeutics Q3 Sales $41.47M Beat $38.27M Estimate
Benzinga Newsdesk
-
Nov 2, 2023, 5:06PM
Earnings Scheduled For November 2, 2023
Benzinga Insights
-
Nov 2, 2023, 4:56AM
Tuesday, September 05, 2023
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Sep 5, 2023, 1:34PM
Monday, August 14, 2023
Benzinga's Top Ratings Upgrades, Downgrades For August 14, 2023
Benzinga Insights
-
Aug 14, 2023, 11:00AM
Barrington Research Upgrades Anika Therapeutics to Outperform, Announces $24 Price Target
Benzinga Newsdesk
-
Aug 14, 2023, 8:46AM
Thursday, August 10, 2023
Stocks That Hit 52-Week Lows On Thursday
Benzinga Insights
-
Aug 10, 2023, 1:43PM
Stephens & Co. Maintains Equal-Weight on Anika Therapeutics, Lowers Price Target to $23
Benzinga Newsdesk
-
Aug 10, 2023, 10:16AM
Wednesday, August 09, 2023
Stocks That Hit 52-Week Lows On Wednesday
Benzinga Insights
-
Aug 9, 2023, 12:27PM
Tuesday, August 08, 2023
Anika Therapeutics Q2 Adj EPS $0.06 Beats $(0.27) Estimate, Sales $44.30M Beat $40.56M Estimate
Benzinga Newsdesk
-
Aug 8, 2023, 4:43PM
Stocks That Hit 52-Week Lows On Tuesday
Benzinga Insights
-
Aug 8, 2023, 1:32PM
Earnings Scheduled For August 8, 2023
Benzinga Insights
-
Aug 8, 2023, 4:48AM
Monday, August 07, 2023
Stocks That Hit 52-Week Lows On Monday
Benzinga Insights
-
Aug 7, 2023, 12:13PM
Wednesday, May 31, 2023
Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $28 Price Target
Benzinga Newsdesk
-
May 31, 2023, 8:00AM
Tuesday, May 30, 2023
Anika Completes Enrollment in Hyalofast U.S. Pivotal Phase III Study
Benzinga Newsdesk
-
May 30, 2023, 4:07PM
Tuesday, May 09, 2023
Recap: Anika Therapeutics Q1 Earnings
Benzinga Insights
-
May 9, 2023, 5:20PM
Anika Therapeutics Sees FY23 Revenue $158M-$163M vs $161.06M Est.
Benzinga Newsdesk
-
May 9, 2023, 4:34PM
Anika Therapeutics Q1 EPS $(0.36) Misses $(0.30) Estimate, Sales $37.90M Beat $37.28M Estimate
Benzinga Newsdesk
-
May 9, 2023, 4:34PM
Earnings Scheduled For May 9, 2023
Benzinga Insights
-
May 9, 2023, 6:03AM
Friday, April 14, 2023
Stephens & Co. Reiterates Equal-Weight on Anika Therapeutics, Maintains $28 Price Target
Benzinga Newsdesk
-
Apr 14, 2023, 8:05AM
Thursday, April 13, 2023
Anika Enters Into Cooperation Agreement With Caligan Partners; Board Authorized $20M Share Repurchase Program
Michael Horton
-
Apr 13, 2023, 5:02PM
Monday, April 03, 2023
Anika Continues To Expand Addressable Market For Tactoset Injectable Bone Substitute With Additional 510(k) Clearance From FDA
Happy Mohamed
-
Apr 3, 2023, 9:02AM
Monday, March 27, 2023
Anika Files Preliminary Proxy Statement In Connection With Its Upcoming 2023 Annual Meeting Of Stockholders
Happy Mohamed
-
Mar 27, 2023, 8:57AM
Tuesday, March 07, 2023
Anika Therapeutics shares are trading lower after the company reported Q4 financial results and issued FY23 revenue guidance below analyst estimates.
Michael Horton
-
Mar 7, 2023, 11:29AM
Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023
Benzinga Insights
-
Mar 7, 2023, 10:00AM
Barrington Research Downgrades Anika Therapeutics to Market Perform
Benzinga Newsdesk
-
Mar 7, 2023, 9:32AM
Monday, March 06, 2023
Anika Therapeutics Sees FY23 Revenue $158M-$163M vs $168.4M Est.
Benzinga Newsdesk
-
Mar 6, 2023, 4:12PM
Anika Therapeutics Q4 Adj. EPS $(0.21) Beats $(0.24) Estimate, Sales $39.60M Beat $37.70M Estimate
Benzinga Newsdesk
-
Mar 6, 2023, 4:12PM
Earnings Scheduled For March 6, 2023
Benzinga Insights
-
Mar 6, 2023, 4:52AM
Friday, March 03, 2023
Anika Therapeutics Earnings Preview
Benzinga Insights
-
Mar 3, 2023, 9:02AM
Tuesday, February 21, 2023
Anika Issues Statement In Response To The Letter By Caligan Partners LP
Happy Mohamed
-
Feb 21, 2023, 10:02AM
Anika Shareholder Caligan Issues Open Letter To Board; Urges Actions For Significant Change, Including Strategic Review
Benzinga Newsdesk
-
Feb 21, 2023, 8:13AM
Monday, February 13, 2023
Anika Announces First Surgeries Performed Using the New RevoMotion Reverse Shoulder Arthroplasty System
Benzinga Newsdesk
-
Feb 13, 2023, 8:33AM
Wednesday, November 09, 2022
Anika Therapeutics shares are trading higher after the company reported better-than-expected Q3 EPS and sales results.
Michael Horton
-
Nov 9, 2022, 12:21PM
Barrington Research Upgrades Anika Therapeutics to Outperform, Announces $31 Price Target
Benzinga Newsdesk
-
Nov 9, 2022, 9:26AM
Tuesday, November 08, 2022
Anika Therapeutics Q3 EPS $(0.05) Beats $(0.25) Estimate, Sales $40.26M Beat $37.59M Estimate
Benzinga Newsdesk
-
Nov 8, 2022, 4:12PM
Earnings Scheduled For November 8, 2022
Benzinga Insights
-
Nov 8, 2022, 4:32AM
Tuesday, November 01, 2022
Anika Therapeutics Cingal Tops Steroid For Osteoarthritis Pain Relief
Vandana Singh
-
Nov 1, 2022, 12:14PM
Anika Therapeutics Announces Cingal Met Its Primary Endpoint In Third Phase III Study
Benzinga Newsdesk
-
Nov 1, 2022, 8:05AM
Friday, October 14, 2022
Stephens & Co. Reinstates Equal-Weight on Anika Therapeutics, Announces $26 Price Target
Benzinga Newsdesk
-
Oct 14, 2022, 5:20AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch